nodes	percent_of_prediction	percent_of_DWPC	metapath
Triamcinolone—PTGS2—esophageal cancer	0.494	1	CbGaD
Triamcinolone—BCHE—Cisplatin—esophageal cancer	0.15	0.565	CbGbCtD
Triamcinolone—PTGS2—Cisplatin—esophageal cancer	0.115	0.435	CbGbCtD
Triamcinolone—BCHE—diaphragm—esophageal cancer	0.0126	0.379	CbGeAlD
Triamcinolone—Aseptic necrosis—Methotrexate—esophageal cancer	0.00507	0.0397	CcSEcCtD
Triamcinolone—Paraplegia—Methotrexate—esophageal cancer	0.00432	0.0338	CcSEcCtD
Triamcinolone—Personality change—Capecitabine—esophageal cancer	0.00409	0.0321	CcSEcCtD
Triamcinolone—Diplegia—Methotrexate—esophageal cancer	0.00403	0.0316	CcSEcCtD
Triamcinolone—Glucose tolerance impaired—Cisplatin—esophageal cancer	0.00395	0.031	CcSEcCtD
Triamcinolone—Monoplegia—Methotrexate—esophageal cancer	0.00378	0.0296	CcSEcCtD
Triamcinolone—Papilloedema—Cisplatin—esophageal cancer	0.00335	0.0263	CcSEcCtD
Triamcinolone—Arachnoiditis—Methotrexate—esophageal cancer	0.0032	0.0251	CcSEcCtD
Triamcinolone—Localized exfoliation—Capecitabine—esophageal cancer	0.00291	0.0228	CcSEcCtD
Triamcinolone—Amcinonide—ANXA1—esophageal cancer	0.0021	0.277	CrCbGaD
Triamcinolone—Blindness—Cisplatin—esophageal cancer	0.00192	0.0151	CcSEcCtD
Triamcinolone—Optic neuritis—Cisplatin—esophageal cancer	0.00173	0.0136	CcSEcCtD
Triamcinolone—NR3C1—neck—esophageal cancer	0.00158	0.0473	CbGeAlD
Triamcinolone—Osteonecrosis—Methotrexate—esophageal cancer	0.00157	0.0123	CcSEcCtD
Triamcinolone—SERPINA6—lung—esophageal cancer	0.00156	0.0467	CbGeAlD
Triamcinolone—Sneezing—Capecitabine—esophageal cancer	0.00142	0.0111	CcSEcCtD
Triamcinolone—Leukoderma—Methotrexate—esophageal cancer	0.00137	0.0108	CcSEcCtD
Triamcinolone—Impaired healing—Methotrexate—esophageal cancer	0.00135	0.0106	CcSEcCtD
Triamcinolone—Hirsutism—Capecitabine—esophageal cancer	0.00135	0.0106	CcSEcCtD
Triamcinolone—Abscess—Cisplatin—esophageal cancer	0.00135	0.0106	CcSEcCtD
Triamcinolone—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.00132	0.0103	CcSEcCtD
Triamcinolone—Infection—Carboplatin—esophageal cancer	0.00129	0.0101	CcSEcCtD
Triamcinolone—Embolism—Capecitabine—esophageal cancer	0.00122	0.00959	CcSEcCtD
Triamcinolone—BCHE—bronchus—esophageal cancer	0.00119	0.0356	CbGeAlD
Triamcinolone—BCHE—smooth muscle tissue—esophageal cancer	0.00116	0.0348	CbGeAlD
Triamcinolone—Ulcer—Cisplatin—esophageal cancer	0.00113	0.00883	CcSEcCtD
Triamcinolone—Hepatomegaly—Capecitabine—esophageal cancer	0.00111	0.00869	CcSEcCtD
Triamcinolone—Pain—Carboplatin—esophageal cancer	0.00111	0.00868	CcSEcCtD
Triamcinolone—Blister—Capecitabine—esophageal cancer	0.00109	0.00854	CcSEcCtD
Triamcinolone—Throat sore—Capecitabine—esophageal cancer	0.00109	0.00854	CcSEcCtD
Triamcinolone—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.00108	0.00846	CcSEcCtD
Triamcinolone—NR3C1—epithelium—esophageal cancer	0.00107	0.0322	CbGeAlD
Triamcinolone—BCHE—trachea—esophageal cancer	0.00107	0.032	CbGeAlD
Triamcinolone—Hiccups—Cisplatin—esophageal cancer	0.00106	0.00835	CcSEcCtD
Triamcinolone—NR3C1—bronchus—esophageal cancer	0.00106	0.0317	CbGeAlD
Triamcinolone—Osteoporosis—Methotrexate—esophageal cancer	0.00104	0.00817	CcSEcCtD
Triamcinolone—Wheezing—Cisplatin—esophageal cancer	0.00103	0.00811	CcSEcCtD
Triamcinolone—NR3C1—smooth muscle tissue—esophageal cancer	0.00103	0.031	CbGeAlD
Triamcinolone—Body temperature increased—Carboplatin—esophageal cancer	0.00102	0.00803	CcSEcCtD
Triamcinolone—Skin exfoliation—Cisplatin—esophageal cancer	0.00102	0.00797	CcSEcCtD
Triamcinolone—Fluid retention—Cisplatin—esophageal cancer	0.00101	0.00793	CcSEcCtD
Triamcinolone—Neuropathy—Cisplatin—esophageal cancer	0.001	0.00784	CcSEcCtD
Triamcinolone—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.000982	0.0077	CcSEcCtD
Triamcinolone—Petechiae—Capecitabine—esophageal cancer	0.000954	0.00748	CcSEcCtD
Triamcinolone—NR3C1—trachea—esophageal cancer	0.000949	0.0285	CbGeAlD
Triamcinolone—Folliculitis—Methotrexate—esophageal cancer	0.000929	0.00729	CcSEcCtD
Triamcinolone—PTGS2—epithelium—esophageal cancer	0.000928	0.0279	CbGeAlD
Triamcinolone—BCHE—digestive system—esophageal cancer	0.000917	0.0275	CbGeAlD
Triamcinolone—PTGS2—bronchus—esophageal cancer	0.000914	0.0274	CbGeAlD
Triamcinolone—Embolism—Methotrexate—esophageal cancer	0.00091	0.00714	CcSEcCtD
Triamcinolone—PTGS2—smooth muscle tissue—esophageal cancer	0.000895	0.0268	CbGeAlD
Triamcinolone—Hydrocortisone—ANXA1—esophageal cancer	0.000884	0.117	CrCbGaD
Triamcinolone—Oropharyngeal pain—Capecitabine—esophageal cancer	0.000863	0.00677	CcSEcCtD
Triamcinolone—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000852	0.00668	CcSEcCtD
Triamcinolone—Testolactone—CYP19A1—esophageal cancer	0.000843	0.111	CrCbGaD
Triamcinolone—Ulcer—Capecitabine—esophageal cancer	0.00083	0.00651	CcSEcCtD
Triamcinolone—Cataract—Capecitabine—esophageal cancer	0.000824	0.00646	CcSEcCtD
Triamcinolone—PTGS2—trachea—esophageal cancer	0.000821	0.0246	CbGeAlD
Triamcinolone—NR3C1—digestive system—esophageal cancer	0.000816	0.0245	CbGeAlD
Triamcinolone—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000798	0.00626	CcSEcCtD
Triamcinolone—Hiccups—Capecitabine—esophageal cancer	0.000785	0.00615	CcSEcCtD
Triamcinolone—BCHE—lung—esophageal cancer	0.000766	0.023	CbGeAlD
Triamcinolone—Candida infection—Capecitabine—esophageal cancer	0.000749	0.00587	CcSEcCtD
Triamcinolone—Skin exfoliation—Capecitabine—esophageal cancer	0.000749	0.00587	CcSEcCtD
Triamcinolone—Fluid retention—Capecitabine—esophageal cancer	0.000745	0.00584	CcSEcCtD
Triamcinolone—Abscess—Methotrexate—esophageal cancer	0.000738	0.00579	CcSEcCtD
Triamcinolone—Neuropathy—Capecitabine—esophageal cancer	0.000737	0.00578	CcSEcCtD
Triamcinolone—Petechiae—Methotrexate—esophageal cancer	0.00071	0.00557	CcSEcCtD
Triamcinolone—Ecchymosis—Capecitabine—esophageal cancer	0.00071	0.00556	CcSEcCtD
Triamcinolone—PTGS2—digestive system—esophageal cancer	0.000706	0.0212	CbGeAlD
Triamcinolone—NR3C1—lung—esophageal cancer	0.000682	0.0204	CbGeAlD
Triamcinolone—Dexamethasone—ANXA1—esophageal cancer	0.000659	0.0869	CrCbGaD
Triamcinolone—Thrombophlebitis—Capecitabine—esophageal cancer	0.000658	0.00516	CcSEcCtD
Triamcinolone—Diabetes mellitus—Capecitabine—esophageal cancer	0.000655	0.00514	CcSEcCtD
Triamcinolone—Pancreatitis—Cisplatin—esophageal cancer	0.000655	0.00513	CcSEcCtD
Triamcinolone—Sweating increased—Cisplatin—esophageal cancer	0.000651	0.0051	CcSEcCtD
Triamcinolone—Vascular purpura—Capecitabine—esophageal cancer	0.000637	0.00499	CcSEcCtD
Triamcinolone—Ulcer—Methotrexate—esophageal cancer	0.000618	0.00484	CcSEcCtD
Triamcinolone—CYP3A4—digestive system—esophageal cancer	0.000617	0.0185	CbGeAlD
Triamcinolone—Increased appetite—Capecitabine—esophageal cancer	0.000606	0.00475	CcSEcCtD
Triamcinolone—Vasculitis—Methotrexate—esophageal cancer	0.000599	0.00469	CcSEcCtD
Triamcinolone—Dermatitis bullous—Capecitabine—esophageal cancer	0.000596	0.00467	CcSEcCtD
Triamcinolone—Purpura—Capecitabine—esophageal cancer	0.000591	0.00463	CcSEcCtD
Triamcinolone—PTGS2—lung—esophageal cancer	0.00059	0.0177	CbGeAlD
Triamcinolone—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000587	0.0046	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000584	0.00458	CcSEcCtD
Triamcinolone—Myocardial infarction—Cisplatin—esophageal cancer	0.000584	0.00458	CcSEcCtD
Triamcinolone—Conjunctivitis—Cisplatin—esophageal cancer	0.000579	0.00454	CcSEcCtD
Triamcinolone—Osteoarthritis—Capecitabine—esophageal cancer	0.00057	0.00447	CcSEcCtD
Triamcinolone—Skin exfoliation—Methotrexate—esophageal cancer	0.000558	0.00437	CcSEcCtD
Triamcinolone—Bradycardia—Cisplatin—esophageal cancer	0.000544	0.00427	CcSEcCtD
Triamcinolone—Cardiac arrest—Capecitabine—esophageal cancer	0.000542	0.00425	CcSEcCtD
Triamcinolone—Mood swings—Capecitabine—esophageal cancer	0.00054	0.00423	CcSEcCtD
Triamcinolone—Ecchymosis—Methotrexate—esophageal cancer	0.000528	0.00414	CcSEcCtD
Triamcinolone—BCHE—lymph node—esophageal cancer	0.000524	0.0157	CbGeAlD
Triamcinolone—Pulmonary oedema—Methotrexate—esophageal cancer	0.00052	0.00408	CcSEcCtD
Triamcinolone—Muscular weakness—Capecitabine—esophageal cancer	0.000502	0.00394	CcSEcCtD
Triamcinolone—Abdominal distension—Capecitabine—esophageal cancer	0.000496	0.00389	CcSEcCtD
Triamcinolone—Asthma—Capecitabine—esophageal cancer	0.000492	0.00386	CcSEcCtD
Triamcinolone—Influenza—Capecitabine—esophageal cancer	0.000492	0.00386	CcSEcCtD
Triamcinolone—Thrombophlebitis—Methotrexate—esophageal cancer	0.00049	0.00384	CcSEcCtD
Triamcinolone—Diabetes mellitus—Methotrexate—esophageal cancer	0.000488	0.00382	CcSEcCtD
Triamcinolone—Sweating increased—Capecitabine—esophageal cancer	0.00048	0.00376	CcSEcCtD
Triamcinolone—Arrhythmia—Cisplatin—esophageal cancer	0.000478	0.00374	CcSEcCtD
Triamcinolone—Bronchitis—Capecitabine—esophageal cancer	0.000473	0.00371	CcSEcCtD
Triamcinolone—NR3C1—lymph node—esophageal cancer	0.000466	0.014	CbGeAlD
Triamcinolone—Erythema—Cisplatin—esophageal cancer	0.000465	0.00365	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000458	0.00359	CcSEcCtD
Triamcinolone—Weight increased—Capecitabine—esophageal cancer	0.000448	0.00351	CcSEcCtD
Triamcinolone—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000438	0.00344	CcSEcCtD
Triamcinolone—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000433	0.00339	CcSEcCtD
Triamcinolone—Ill-defined disorder—Cisplatin—esophageal cancer	0.000432	0.00339	CcSEcCtD
Triamcinolone—Myocardial infarction—Capecitabine—esophageal cancer	0.00043	0.00337	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00043	0.00337	CcSEcCtD
Triamcinolone—Conjunctivitis—Capecitabine—esophageal cancer	0.000427	0.00335	CcSEcCtD
Triamcinolone—Osteoarthritis—Methotrexate—esophageal cancer	0.000424	0.00333	CcSEcCtD
Triamcinolone—Malaise—Cisplatin—esophageal cancer	0.00042	0.00329	CcSEcCtD
Triamcinolone—Epistaxis—Capecitabine—esophageal cancer	0.000414	0.00325	CcSEcCtD
Triamcinolone—PTGS2—lymph node—esophageal cancer	0.000403	0.0121	CbGeAlD
Triamcinolone—Convulsion—Cisplatin—esophageal cancer	0.000403	0.00316	CcSEcCtD
Triamcinolone—Mood swings—Methotrexate—esophageal cancer	0.000402	0.00315	CcSEcCtD
Triamcinolone—Bradycardia—Capecitabine—esophageal cancer	0.000401	0.00315	CcSEcCtD
Triamcinolone—Myalgia—Cisplatin—esophageal cancer	0.000396	0.00311	CcSEcCtD
Triamcinolone—Haemoglobin—Capecitabine—esophageal cancer	0.000396	0.00311	CcSEcCtD
Triamcinolone—Rhinitis—Capecitabine—esophageal cancer	0.000395	0.0031	CcSEcCtD
Triamcinolone—Haemorrhage—Capecitabine—esophageal cancer	0.000394	0.00309	CcSEcCtD
Triamcinolone—Discomfort—Cisplatin—esophageal cancer	0.000391	0.00307	CcSEcCtD
Triamcinolone—Pharyngitis—Capecitabine—esophageal cancer	0.000391	0.00307	CcSEcCtD
Triamcinolone—Oedema—Cisplatin—esophageal cancer	0.00038	0.00298	CcSEcCtD
Triamcinolone—Anaphylactic shock—Cisplatin—esophageal cancer	0.00038	0.00298	CcSEcCtD
Triamcinolone—Infection—Cisplatin—esophageal cancer	0.000377	0.00296	CcSEcCtD
Triamcinolone—Tachycardia—Cisplatin—esophageal cancer	0.000371	0.00291	CcSEcCtD
Triamcinolone—Hyperhidrosis—Cisplatin—esophageal cancer	0.000367	0.00288	CcSEcCtD
Triamcinolone—Asthma—Methotrexate—esophageal cancer	0.000367	0.00287	CcSEcCtD
Triamcinolone—Pancreatitis—Methotrexate—esophageal cancer	0.000359	0.00282	CcSEcCtD
Triamcinolone—Prednisolone—CYP2A6—esophageal cancer	0.000355	0.0468	CrCbGaD
Triamcinolone—Arrhythmia—Capecitabine—esophageal cancer	0.000352	0.00276	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000346	0.00271	CcSEcCtD
Triamcinolone—Erythema—Capecitabine—esophageal cancer	0.000343	0.00269	CcSEcCtD
Triamcinolone—Paraesthesia—Cisplatin—esophageal cancer	0.000341	0.00267	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000341	0.00267	CcSEcCtD
Triamcinolone—Dyspnoea—Cisplatin—esophageal cancer	0.000339	0.00266	CcSEcCtD
Triamcinolone—Dysgeusia—Capecitabine—esophageal cancer	0.000336	0.00263	CcSEcCtD
Triamcinolone—Back pain—Capecitabine—esophageal cancer	0.000332	0.0026	CcSEcCtD
Triamcinolone—Betamethasone—CYP19A1—esophageal cancer	0.000331	0.0436	CrCbGaD
Triamcinolone—Pain—Cisplatin—esophageal cancer	0.000325	0.00255	CcSEcCtD
Triamcinolone—Ill-defined disorder—Capecitabine—esophageal cancer	0.000318	0.0025	CcSEcCtD
Triamcinolone—Conjunctivitis—Methotrexate—esophageal cancer	0.000318	0.00249	CcSEcCtD
Triamcinolone—Feeling abnormal—Cisplatin—esophageal cancer	0.000313	0.00245	CcSEcCtD
Triamcinolone—Malaise—Capecitabine—esophageal cancer	0.000309	0.00243	CcSEcCtD
Triamcinolone—Dexamethasone—NOS2—esophageal cancer	0.000308	0.0407	CrCbGaD
Triamcinolone—Epistaxis—Methotrexate—esophageal cancer	0.000308	0.00242	CcSEcCtD
Triamcinolone—Vertigo—Capecitabine—esophageal cancer	0.000308	0.00242	CcSEcCtD
Triamcinolone—Syncope—Capecitabine—esophageal cancer	0.000308	0.00241	CcSEcCtD
Triamcinolone—Loss of consciousness—Capecitabine—esophageal cancer	0.000302	0.00236	CcSEcCtD
Triamcinolone—Body temperature increased—Cisplatin—esophageal cancer	0.0003	0.00235	CcSEcCtD
Triamcinolone—Cough—Capecitabine—esophageal cancer	0.000299	0.00235	CcSEcCtD
Triamcinolone—Hypertension—Capecitabine—esophageal cancer	0.000296	0.00232	CcSEcCtD
Triamcinolone—Haemoglobin—Methotrexate—esophageal cancer	0.000295	0.00231	CcSEcCtD
Triamcinolone—Haemorrhage—Methotrexate—esophageal cancer	0.000293	0.0023	CcSEcCtD
Triamcinolone—Myalgia—Capecitabine—esophageal cancer	0.000292	0.00229	CcSEcCtD
Triamcinolone—Pharyngitis—Methotrexate—esophageal cancer	0.000291	0.00228	CcSEcCtD
Triamcinolone—Discomfort—Capecitabine—esophageal cancer	0.000289	0.00226	CcSEcCtD
Triamcinolone—Dry mouth—Capecitabine—esophageal cancer	0.000286	0.00224	CcSEcCtD
Triamcinolone—Oedema—Capecitabine—esophageal cancer	0.00028	0.0022	CcSEcCtD
Triamcinolone—Hypersensitivity—Cisplatin—esophageal cancer	0.00028	0.00219	CcSEcCtD
Triamcinolone—Infection—Capecitabine—esophageal cancer	0.000278	0.00218	CcSEcCtD
Triamcinolone—Shock—Capecitabine—esophageal cancer	0.000275	0.00216	CcSEcCtD
Triamcinolone—Tachycardia—Capecitabine—esophageal cancer	0.000273	0.00214	CcSEcCtD
Triamcinolone—Asthenia—Cisplatin—esophageal cancer	0.000273	0.00214	CcSEcCtD
Triamcinolone—Hyperhidrosis—Capecitabine—esophageal cancer	0.000271	0.00212	CcSEcCtD
Triamcinolone—Dexamethasone—CYP1B1—esophageal cancer	0.000262	0.0346	CrCbGaD
Triamcinolone—Erythema—Methotrexate—esophageal cancer	0.000255	0.002	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000255	0.002	CcSEcCtD
Triamcinolone—Insomnia—Capecitabine—esophageal cancer	0.000253	0.00199	CcSEcCtD
Triamcinolone—Paraesthesia—Capecitabine—esophageal cancer	0.000251	0.00197	CcSEcCtD
Triamcinolone—Dysgeusia—Methotrexate—esophageal cancer	0.00025	0.00196	CcSEcCtD
Triamcinolone—Dyspnoea—Capecitabine—esophageal cancer	0.00025	0.00196	CcSEcCtD
Triamcinolone—Back pain—Methotrexate—esophageal cancer	0.000247	0.00194	CcSEcCtD
Triamcinolone—Dyspepsia—Capecitabine—esophageal cancer	0.000246	0.00193	CcSEcCtD
Triamcinolone—Vomiting—Cisplatin—esophageal cancer	0.000241	0.00189	CcSEcCtD
Triamcinolone—Fatigue—Capecitabine—esophageal cancer	0.000241	0.00189	CcSEcCtD
Triamcinolone—Rash—Cisplatin—esophageal cancer	0.000239	0.00188	CcSEcCtD
Triamcinolone—Pain—Capecitabine—esophageal cancer	0.000239	0.00188	CcSEcCtD
Triamcinolone—Dermatitis—Cisplatin—esophageal cancer	0.000239	0.00188	CcSEcCtD
Triamcinolone—Ill-defined disorder—Methotrexate—esophageal cancer	0.000237	0.00186	CcSEcCtD
Triamcinolone—Fluticasone furoate—ABCB1—esophageal cancer	0.000235	0.031	CrCbGaD
Triamcinolone—Feeling abnormal—Capecitabine—esophageal cancer	0.000231	0.00181	CcSEcCtD
Triamcinolone—Malaise—Methotrexate—esophageal cancer	0.00023	0.00181	CcSEcCtD
Triamcinolone—Vertigo—Methotrexate—esophageal cancer	0.000229	0.0018	CcSEcCtD
Triamcinolone—Nausea—Cisplatin—esophageal cancer	0.000226	0.00177	CcSEcCtD
Triamcinolone—Cough—Methotrexate—esophageal cancer	0.000223	0.00175	CcSEcCtD
Triamcinolone—Urticaria—Capecitabine—esophageal cancer	0.000222	0.00174	CcSEcCtD
Triamcinolone—Body temperature increased—Capecitabine—esophageal cancer	0.000221	0.00174	CcSEcCtD
Triamcinolone—Convulsion—Methotrexate—esophageal cancer	0.000221	0.00174	CcSEcCtD
Triamcinolone—Myalgia—Methotrexate—esophageal cancer	0.000217	0.0017	CcSEcCtD
Triamcinolone—Discomfort—Methotrexate—esophageal cancer	0.000215	0.00168	CcSEcCtD
Triamcinolone—Anaphylactic shock—Methotrexate—esophageal cancer	0.000208	0.00163	CcSEcCtD
Triamcinolone—Infection—Methotrexate—esophageal cancer	0.000207	0.00162	CcSEcCtD
Triamcinolone—Hypersensitivity—Capecitabine—esophageal cancer	0.000206	0.00162	CcSEcCtD
Triamcinolone—Dexamethasone—ABCC2—esophageal cancer	0.000205	0.027	CrCbGaD
Triamcinolone—Dexamethasone—CYP2A6—esophageal cancer	0.000202	0.0267	CrCbGaD
Triamcinolone—Hyperhidrosis—Methotrexate—esophageal cancer	0.000201	0.00158	CcSEcCtD
Triamcinolone—Asthenia—Capecitabine—esophageal cancer	0.000201	0.00158	CcSEcCtD
Triamcinolone—Pruritus—Capecitabine—esophageal cancer	0.000198	0.00155	CcSEcCtD
Triamcinolone—Dexamethasone—CYP19A1—esophageal cancer	0.000192	0.0254	CrCbGaD
Triamcinolone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00019	0.00149	CcSEcCtD
Triamcinolone—Insomnia—Methotrexate—esophageal cancer	0.000189	0.00148	CcSEcCtD
Triamcinolone—Methylprednisolone—ABCB1—esophageal cancer	0.000187	0.0247	CrCbGaD
Triamcinolone—Paraesthesia—Methotrexate—esophageal cancer	0.000187	0.00147	CcSEcCtD
Triamcinolone—Dyspnoea—Methotrexate—esophageal cancer	0.000186	0.00146	CcSEcCtD
Triamcinolone—Dizziness—Capecitabine—esophageal cancer	0.000185	0.00145	CcSEcCtD
Triamcinolone—Dyspepsia—Methotrexate—esophageal cancer	0.000183	0.00144	CcSEcCtD
Triamcinolone—Fatigue—Methotrexate—esophageal cancer	0.00018	0.00141	CcSEcCtD
Triamcinolone—Pain—Methotrexate—esophageal cancer	0.000178	0.0014	CcSEcCtD
Triamcinolone—Vomiting—Capecitabine—esophageal cancer	0.000178	0.0014	CcSEcCtD
Triamcinolone—Rash—Capecitabine—esophageal cancer	0.000177	0.00138	CcSEcCtD
Triamcinolone—Dermatitis—Capecitabine—esophageal cancer	0.000176	0.00138	CcSEcCtD
Triamcinolone—Headache—Capecitabine—esophageal cancer	0.000175	0.00138	CcSEcCtD
Triamcinolone—Feeling abnormal—Methotrexate—esophageal cancer	0.000172	0.00135	CcSEcCtD
Triamcinolone—Nausea—Capecitabine—esophageal cancer	0.000166	0.0013	CcSEcCtD
Triamcinolone—Urticaria—Methotrexate—esophageal cancer	0.000166	0.0013	CcSEcCtD
Triamcinolone—Body temperature increased—Methotrexate—esophageal cancer	0.000165	0.00129	CcSEcCtD
Triamcinolone—Hypersensitivity—Methotrexate—esophageal cancer	0.000154	0.0012	CcSEcCtD
Triamcinolone—Betamethasone—PTGS2—esophageal cancer	0.000152	0.0201	CrCbGaD
Triamcinolone—Asthenia—Methotrexate—esophageal cancer	0.00015	0.00117	CcSEcCtD
Triamcinolone—Pruritus—Methotrexate—esophageal cancer	0.000147	0.00116	CcSEcCtD
Triamcinolone—NR3C1—Adipogenesis—HIF1A—esophageal cancer	0.000147	0.00202	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—CCND1—esophageal cancer	0.000145	0.00201	CbGpPWpGaD
Triamcinolone—Prednisone—ABCB1—esophageal cancer	0.000143	0.0189	CrCbGaD
Triamcinolone—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000143	0.00197	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000142	0.00196	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.00014	0.00193	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—NR1I2—esophageal cancer	0.000138	0.00191	CbGpPWpGaD
Triamcinolone—Dizziness—Methotrexate—esophageal cancer	0.000138	0.00108	CcSEcCtD
Triamcinolone—BCHE—Metabolism of proteins—XBP1—esophageal cancer	0.000136	0.00187	CbGpPWpGaD
Triamcinolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000134	0.00186	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—EP300—esophageal cancer	0.000134	0.00185	CbGpPWpGaD
Triamcinolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000134	0.00185	CbGpPWpGaD
Triamcinolone—Vomiting—Methotrexate—esophageal cancer	0.000133	0.00104	CcSEcCtD
Triamcinolone—Prednisolone—ABCB1—esophageal cancer	0.000132	0.0174	CrCbGaD
Triamcinolone—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000132	0.00182	CbGpPWpGaD
Triamcinolone—Rash—Methotrexate—esophageal cancer	0.000131	0.00103	CcSEcCtD
Triamcinolone—Dermatitis—Methotrexate—esophageal cancer	0.000131	0.00103	CcSEcCtD
Triamcinolone—Headache—Methotrexate—esophageal cancer	0.000131	0.00102	CcSEcCtD
Triamcinolone—BCHE—Metabolism of proteins—SLC30A7—esophageal cancer	0.00013	0.0018	CbGpPWpGaD
Triamcinolone—Betamethasone—ABCB1—esophageal cancer	0.000129	0.0171	CrCbGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—CREBBP—esophageal cancer	0.000129	0.00178	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000128	0.00177	CbGpPWpGaD
Triamcinolone—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000127	0.00176	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000127	0.00176	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000127	0.00175	CbGpPWpGaD
Triamcinolone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—esophageal cancer	0.000126	0.00174	CbGpPWpGaD
Triamcinolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000126	0.00174	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—esophageal cancer	0.000125	0.00173	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000125	0.00172	CbGpPWpGaD
Triamcinolone—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000124	0.00171	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—esophageal cancer	0.000124	0.00171	CbGpPWpGaD
Triamcinolone—Nausea—Methotrexate—esophageal cancer	0.000124	0.000971	CcSEcCtD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000124	0.00171	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000123	0.0017	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000122	0.00168	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000121	0.00167	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—RB1—esophageal cancer	0.000119	0.00165	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—esophageal cancer	0.000119	0.00164	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—EP300—esophageal cancer	0.000118	0.00163	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—ST6GAL1—esophageal cancer	0.000117	0.00162	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—MYC—esophageal cancer	0.000117	0.00161	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—TLR4—esophageal cancer	0.000115	0.00159	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—CDKN2A—esophageal cancer	0.000113	0.00156	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—BCL2—esophageal cancer	0.000111	0.00153	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—NOS2—esophageal cancer	0.000109	0.00151	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000109	0.0015	CbGpPWpGaD
Triamcinolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000108	0.0015	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000108	0.00149	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—esophageal cancer	0.000104	0.00143	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000103	0.00143	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000103	0.00142	CbGpPWpGaD
Triamcinolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000102	0.00141	CbGpPWpGaD
Triamcinolone—Hydrocortisone—ABCB1—esophageal cancer	0.000101	0.0133	CrCbGaD
Triamcinolone—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.0001	0.00138	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	9.98e-05	0.00138	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	9.98e-05	0.00138	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	9.88e-05	0.00136	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—RB1—esophageal cancer	9.77e-05	0.00135	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—BLVRB—esophageal cancer	9.67e-05	0.00134	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—SLC52A3—esophageal cancer	9.67e-05	0.00134	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—TP53—esophageal cancer	9.58e-05	0.00132	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—CCND1—esophageal cancer	9.52e-05	0.00131	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	9.44e-05	0.0013	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	9.32e-05	0.00129	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—CDKN1A—esophageal cancer	9.21e-05	0.00127	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	9.19e-05	0.00127	CbGpPWpGaD
Triamcinolone—Dexamethasone—PTGS2—esophageal cancer	8.85e-05	0.0117	CrCbGaD
Triamcinolone—NR3C1—Gene Expression—SMG6—esophageal cancer	8.79e-05	0.00121	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—EP300—esophageal cancer	8.76e-05	0.00121	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—NOTCH3—esophageal cancer	8.69e-05	0.0012	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	8.65e-05	0.00119	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	8.59e-05	0.00119	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—CDKN1A—esophageal cancer	8.57e-05	0.00118	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—TP53—esophageal cancer	8.44e-05	0.00116	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CA1—esophageal cancer	8.23e-05	0.00114	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—SLC10A2—esophageal cancer	8.23e-05	0.00114	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—ACTB—esophageal cancer	8.07e-05	0.00111	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—SLC52A3—esophageal cancer	7.95e-05	0.0011	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—NOTCH2—esophageal cancer	7.79e-05	0.00108	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—MYC—esophageal cancer	7.64e-05	0.00105	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	7.6e-05	0.00105	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—KMT2D—esophageal cancer	7.58e-05	0.00105	CbGpPWpGaD
Triamcinolone—Dexamethasone—ABCB1—esophageal cancer	7.52e-05	0.00993	CrCbGaD
Triamcinolone—BCHE—Metabolism—CA2—esophageal cancer	7.52e-05	0.00104	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	7.49e-05	0.00103	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	7.35e-05	0.00102	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—HSPA5—esophageal cancer	7.29e-05	0.00101	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CCND1—esophageal cancer	7.26e-05	0.001	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	7.22e-05	0.000997	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	7.14e-05	0.000986	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—CALR—esophageal cancer	7.07e-05	0.000976	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—EP300—esophageal cancer	7.05e-05	0.000973	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PLCE1—esophageal cancer	6.99e-05	0.000966	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—ADH7—esophageal cancer	6.99e-05	0.000966	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—GHRL—esophageal cancer	6.95e-05	0.000959	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	6.91e-05	0.000954	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—FBXW7—esophageal cancer	6.83e-05	0.000944	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	6.77e-05	0.000935	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	6.7e-05	0.000925	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	6.67e-05	0.000921	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—NR1I2—esophageal cancer	6.66e-05	0.000919	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—BLVRB—esophageal cancer	6.66e-05	0.000919	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—SLC52A3—esophageal cancer	6.66e-05	0.000919	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—SMAD4—esophageal cancer	6.54e-05	0.000903	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—PIK3CA—esophageal cancer	6.33e-05	0.000874	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—ADH1B—esophageal cancer	6.13e-05	0.000847	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	5.95e-05	0.000822	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—FKBP1A—esophageal cancer	5.88e-05	0.000812	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—TYMP—esophageal cancer	5.86e-05	0.000809	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—MYC—esophageal cancer	5.82e-05	0.000803	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	5.76e-05	0.000795	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	5.75e-05	0.000794	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—DOCK2—esophageal cancer	5.75e-05	0.000794	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—WIF1—esophageal cancer	5.75e-05	0.000794	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—HIST1H2BM—esophageal cancer	5.71e-05	0.000789	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CYP26A1—esophageal cancer	5.7e-05	0.000787	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—EGFR—esophageal cancer	5.69e-05	0.000786	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	5.68e-05	0.000784	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CA1—esophageal cancer	5.66e-05	0.000782	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—SLC10A2—esophageal cancer	5.66e-05	0.000782	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	5.59e-05	0.000771	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—ALOX15—esophageal cancer	5.56e-05	0.000767	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	5.41e-05	0.000747	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	5.34e-05	0.000737	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CSNK1A1—esophageal cancer	5.3e-05	0.000732	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—GSTO1—esophageal cancer	5.3e-05	0.000732	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—TPI1—esophageal cancer	5.3e-05	0.000732	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CA2—esophageal cancer	5.18e-05	0.000715	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—ALDOB—esophageal cancer	5.08e-05	0.000702	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	5.06e-05	0.000699	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	4.94e-05	0.000681	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—GAPDH—esophageal cancer	4.89e-05	0.000675	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CRABP1—esophageal cancer	4.85e-05	0.000669	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—NOTCH1—esophageal cancer	4.82e-05	0.000666	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—ADH7—esophageal cancer	4.81e-05	0.000665	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PLCE1—esophageal cancer	4.81e-05	0.000665	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—TP53—esophageal cancer	4.78e-05	0.00066	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.77e-05	0.000659	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.76e-05	0.000657	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—GNG7—esophageal cancer	4.61e-05	0.000637	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	4.54e-05	0.000627	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—ELMO1—esophageal cancer	4.46e-05	0.000615	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—PSME2—esophageal cancer	4.43e-05	0.000612	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—PSME1—esophageal cancer	4.43e-05	0.000612	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—CREBBP—esophageal cancer	4.37e-05	0.000604	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—GSTO1—esophageal cancer	4.36e-05	0.000601	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—TPI1—esophageal cancer	4.36e-05	0.000601	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—ALDH2—esophageal cancer	4.32e-05	0.000597	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—ADH1B—esophageal cancer	4.22e-05	0.000583	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—NOTCH3—esophageal cancer	4.18e-05	0.000577	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—ALDOB—esophageal cancer	4.18e-05	0.000577	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—GSTT1—esophageal cancer	4.11e-05	0.000567	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CYP2A6—esophageal cancer	4.06e-05	0.000561	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	4.05e-05	0.000559	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—TYMP—esophageal cancer	4.03e-05	0.000557	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—HIST1H2BM—esophageal cancer	4.02e-05	0.000555	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—GAPDH—esophageal cancer	4.02e-05	0.000555	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.96e-05	0.000547	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CYP26A1—esophageal cancer	3.92e-05	0.000542	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.87e-05	0.000535	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—ENO1—esophageal cancer	3.85e-05	0.000532	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PTGS1—esophageal cancer	3.85e-05	0.000532	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—ALOX15—esophageal cancer	3.82e-05	0.000528	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PSME2—esophageal cancer	3.79e-05	0.000524	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PSME1—esophageal cancer	3.79e-05	0.000524	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—NOTCH2—esophageal cancer	3.75e-05	0.000518	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—TPI1—esophageal cancer	3.65e-05	0.000504	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—GSTO1—esophageal cancer	3.65e-05	0.000504	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—XIAP—esophageal cancer	3.55e-05	0.00049	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—ALDOB—esophageal cancer	3.5e-05	0.000483	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—GAPDH—esophageal cancer	3.37e-05	0.000465	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.36e-05	0.000464	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CRABP1—esophageal cancer	3.34e-05	0.000461	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.31e-05	0.000458	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—B2M—esophageal cancer	3.3e-05	0.000456	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CYP1B1—esophageal cancer	3.27e-05	0.000452	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.25e-05	0.000449	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—GNG7—esophageal cancer	3.17e-05	0.000438	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—ENO1—esophageal cancer	3.17e-05	0.000437	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—SMAD4—esophageal cancer	3.15e-05	0.000435	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PSME1—esophageal cancer	3.12e-05	0.000431	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PSME2—esophageal cancer	3.12e-05	0.000431	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CYP19A1—esophageal cancer	3.08e-05	0.000425	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CALR—esophageal cancer	2.99e-05	0.000413	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—ALDH2—esophageal cancer	2.97e-05	0.000411	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—SLC52A3—esophageal cancer	2.91e-05	0.000401	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—BLVRB—esophageal cancer	2.91e-05	0.000401	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—FBXW7—esophageal cancer	2.89e-05	0.0004	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—GSTT1—esophageal cancer	2.83e-05	0.000391	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—HMOX1—esophageal cancer	2.81e-05	0.000388	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CYP2A6—esophageal cancer	2.8e-05	0.000386	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.79e-05	0.000385	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.76e-05	0.000381	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—ABCB1—esophageal cancer	2.7e-05	0.000372	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—ENO1—esophageal cancer	2.65e-05	0.000366	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PTGS1—esophageal cancer	2.65e-05	0.000366	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PSME1—esophageal cancer	2.61e-05	0.000361	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PSME2—esophageal cancer	2.61e-05	0.000361	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—MYC—esophageal cancer	2.59e-05	0.000358	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CA1—esophageal cancer	2.47e-05	0.000341	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—SLC10A2—esophageal cancer	2.47e-05	0.000341	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—TGFBR2—esophageal cancer	2.34e-05	0.000323	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—NOTCH1—esophageal cancer	2.32e-05	0.000321	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CA2—esophageal cancer	2.26e-05	0.000312	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CYP1B1—esophageal cancer	2.25e-05	0.000311	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—SMAD4—esophageal cancer	2.22e-05	0.000306	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CYP19A1—esophageal cancer	2.12e-05	0.000293	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—CREBBP—esophageal cancer	2.11e-05	0.000291	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—ADH7—esophageal cancer	2.1e-05	0.00029	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PLCE1—esophageal cancer	2.1e-05	0.00029	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.04e-05	0.000281	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—HMOX1—esophageal cancer	1.93e-05	0.000267	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.9e-05	0.000262	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—ABCB1—esophageal cancer	1.86e-05	0.000256	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.84e-05	0.000255	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—HIF1A—esophageal cancer	1.81e-05	0.00025	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CREBBP—esophageal cancer	1.8e-05	0.000249	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—TYMP—esophageal cancer	1.76e-05	0.000243	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.71e-05	0.000237	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.67e-05	0.000231	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—NOS2—esophageal cancer	1.65e-05	0.000228	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—NOTCH1—esophageal cancer	1.63e-05	0.000226	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—NOS3—esophageal cancer	1.61e-05	0.000223	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.59e-05	0.00022	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—TPI1—esophageal cancer	1.59e-05	0.00022	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.53e-05	0.000211	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CREBBP—esophageal cancer	1.48e-05	0.000205	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PTGS2—esophageal cancer	1.48e-05	0.000204	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.47e-05	0.000203	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.46e-05	0.000201	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.4e-05	0.000194	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—GNG7—esophageal cancer	1.39e-05	0.000191	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—NOS3—esophageal cancer	1.33e-05	0.000183	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.3e-05	0.000179	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—MYC—esophageal cancer	1.25e-05	0.000172	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CREBBP—esophageal cancer	1.24e-05	0.000171	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—ERBB2—esophageal cancer	1.24e-05	0.000171	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.24e-05	0.000171	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—EP300—esophageal cancer	1.23e-05	0.000169	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.22e-05	0.000169	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—ENO1—esophageal cancer	1.16e-05	0.00016	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.16e-05	0.00016	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PSME2—esophageal cancer	1.14e-05	0.000157	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PSME1—esophageal cancer	1.14e-05	0.000157	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—NOS3—esophageal cancer	1.11e-05	0.000153	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CDKN1A—esophageal cancer	1.06e-05	0.000146	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—EP300—esophageal cancer	1.01e-05	0.000139	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CYP1B1—esophageal cancer	9.84e-06	0.000136	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CYP19A1—esophageal cancer	9.26e-06	0.000128	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PIK3CA—esophageal cancer	9.08e-06	0.000125	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—MYC—esophageal cancer	8.79e-06	0.000121	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—EGFR—esophageal cancer	8.6e-06	0.000119	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—EP300—esophageal cancer	8.45e-06	0.000117	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—HMOX1—esophageal cancer	8.45e-06	0.000117	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—ABCB1—esophageal cancer	8.11e-06	0.000112	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PIK3CA—esophageal cancer	7.46e-06	0.000103	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PIK3CA—esophageal cancer	6.25e-06	8.63e-05	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CREBBP—esophageal cancer	5.42e-06	7.48e-05	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—NOS3—esophageal cancer	4.85e-06	6.7e-05	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PTGS2—esophageal cancer	4.44e-06	6.13e-05	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—EP300—esophageal cancer	3.69e-06	5.09e-05	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.73e-06	3.77e-05	CbGpPWpGaD
